Amoy Diagnostics

16 articles about Amoy Diagnostics

• Alercell® to Distribute AmoyDx® Ros1 Gene Fusion Detection Kit

  8/8/2022

  Alercell ® announced today that it has started the distribution of AmoyDx ROS1 Gene Fusion Detection Kit. Part of the master distribution agreement with Amoy Diagnostics Co., Ltd (AmoyDx), signed last month.

• 

  Global Roundup: BenevolentAI Takes on Dengue Fever in New Partnership

  4/21/2022

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

• AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)

  8/17/2021

  Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the Ministry of Health, Labour and Welfare has approved the AmoyDx® Pan Lung Cancer PCR Panel as a companion diagnostic for TEPMETKO® a Merck KGaA, Darmstadt, Germany product that received approval by the Japanese MHLW in March 2020.

• AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer

  6/30/2021

  Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the AmoyDx® Pan Lung Cancer PCR Panel, an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare for production and marketing in Japan on June 25, 2021.

• AmoyDx Lung Cancer PCR Panel accepted into LC-SCRUM as Screening Test for Pharma Clinical Trials in Japan

  9/30/2019

  Amoy Diagnostics Co., Ltd (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that the AmoyDx Lung Cancer PCR Panel has been accepted as first-line screening for patients who will potentially benefit from targeted therapy in the Lung Cancer Genomic Screening Project for Individualized Medicine (LC-SCRUM) in Japan.

• AmoyDx and PREMIA Jointly Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network

  6/24/2019

  AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia to support LOXO-292 RET inhibitor clinical development leveraging AmoyDx’s proprietary multi-gene polymerase chain reaction (PCR) and next generation sequencing (NGS) panels to identify patients with this rare genetic alteration.

• AmoyDx's Plasmid Diagnostic for EGFR Mutations Approved in China

  1/26/2018

  Last year, AmoyDx's EGFR diagnostic was approved for use in the EU.

• China FDA Grants Liquid Biopsy Approval to AmoyDx Super-ARMS EGFR Mutation Test

  1/22/2018

  Amoy Diagnostics announced that CFDA approved its Super-ARMS EGFR Mutation Test for use with plasma samples, as a companion diagnostic for NSCLC therapy with EGFR-TKIs on January 19.

• Amoy Diagnostics Co. LTD. Starts IPO On Shenzhen Stock Exchange

  8/8/2017

• Amoy Diagnostics Co. LTD. ROS1 Diagnostics Test Contributed To A Phase 2 Clinical Study Of Crizotinib In Lung Cancer

  6/15/2016

• Amoy Diagnostics Co. LTD. Got CFDA Approval For Its ROS1 And ALK&ROS1 Testing Kits

  9/3/2014

• Amoy Diagnostics Co. LTD. to Supply ROS1 Diagnostic Kits for Pivotal Clinical Trial of Crizotinib in Asia

  8/29/2013

• SFDA Approval for Amoy Diagnostics Co. LTD.'s EML4-ALK Test

  3/22/2013

• CE Marking for Amoy Diagnostics Co. LTD.'s EML4-ALK Test

  1/2/2013

• New Lung Cancer Mutation Panel from Amoy Diagnostics Co. LTD.

  9/20/2011

• Amoy Diagnostics Co. LTD. and AstraZeneca PLC Co-host Physician Workshop

  9/9/2011